Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,39100Cr 168.73Cr 146.19Cr 136.97Cr 124.93Cr 234.87Cr 16TCr 238.48Cr 1.61TCr 629.72Cr 8.06TCr 633.51Cr 619.75Cr 27TCr P/E 2026 *
-73.3x
P/E 2027 * -75.4x
Enterprise Value 2,39100Cr 168.73Cr 146.19Cr 136.97Cr 124.93Cr 234.87Cr 16TCr 238.48Cr 1.61TCr 629.72Cr 8.06TCr 633.51Cr 619.75Cr 27TCr EV / Sales 2026 *
299x
EV / Sales 2027 * 217x
Free-Float
83.34%
Yield 2026 *
-
Yield 2027 * -
30/07 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
08/07 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
29/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
04/06 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
01/06 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
15/05 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
16/03 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
08/02 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
02/12 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
14/11 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/25/28 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/25/14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-13.95%
1 week-5.26%
Current month+19.73%
1 month-7.87%
3 months-33.39%
6 months-12.02%
Current year-19.16%
1 week 1,10,100
Extreme 110100
1,41,400
1 month 86,600
Extreme 86600
1,41,800
Current year 86,600
Extreme 86600
2,17,000
1 year 50,300
Extreme 50300
2,17,000
3 years 8,280
Extreme 8280
2,17,000
5 years 8,280
Extreme 8280
2,17,000
10 years 8,280
Extreme 8280
2,17,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 61 19/03/2019
Director/Board Member 55 19/03/2019
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap.
28/02/25 Fiscal year

Director

30,000 0.1625%
28/02/25 Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-13.95%-5.26%+128.83%+589.97% 196.67Cr
-0.73%+12.52%+74.33%+102.34% 7.05TCr
+1.60%+1.66%+37.76%+66.48% 5.41TCr
+0.96%+35.83%+10.24%+503.12% 2.9TCr
-0.61%+12.95%+53.77%+5.42% 2.4TCr
+0.39%+1.48%-15.73%-12.94% 2.33TCr
-1.37%+18.52%+255.24%+464.53% 1.87TCr
+2.21%+7.66%+47.18%-19.64% 1.84TCr
0.00%+9.69%+31.01%+584.59% 1.61TCr
+0.06%-9.33%+35.47%+139.01% 1.27TCr
Average -1.13%+7.48%+65.81%+242.29% 2.69TCr
Weighted average by Cap. +0.19%+9.99%+57.09%+170.66%

Financials

2026 *2027 *
Net sales 800Cr 56.46L 48.92L 45.84L 41.81L 78.6L 54Cr 79.81L 5.39Cr 2.11Cr 27Cr 2.12Cr 2.07Cr 90Cr 1.1TCr 77.64L 67.27L 63.02L 57.48L 1.08Cr 74Cr 1.1Cr 7.41Cr 2.9Cr 37Cr 2.91Cr 2.85Cr 123.63Cr
Net income -3.1TCr -2.19Cr -1.9Cr -1.78Cr -1.62Cr -3.05Cr -208.69Cr -3.09Cr -21Cr -8.17Cr -104.49Cr -8.21Cr -8.04Cr -348.43Cr -3TCr -2.12Cr -1.83Cr -1.72Cr -1.57Cr -2.95Cr -201.95Cr -2.99Cr -20Cr -7.9Cr -101.12Cr -7.95Cr -7.78Cr -337.19Cr
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
12/26/12 1,13,500.00 -13.95% 6,24,730
11/26/11 ₩1,31,900.00 -4.28% 3,17,931
10/26/10 ₩1,37,800.00 +13.70% 4,03,251
07/26/07 ₩1,21,200.00 -1.86% 1,51,282
06/26/06 ₩1,23,500.00 +1.65% 1,84,316
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock